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SUPPLEMENTARY MATERIAL 
Sample size calculation 
We used data from a prior study in schizophrenia, which showed an effect size of 1.3 for the 
elevation in associative striatal dopamine synthesis capacity between treatment responders and 
treatment resistant populations1, to inform the power calculation. This determined that a sample 
size of at least 11 would have greater than 80% power to detect a difference between groups, and 
at least 21 to detect a moderate or greater correlation with symptoms both with an alpha value of 
<0.05 (two tailed).  
 
18F-DOPA PET imaging 
All participants were asked not to eat or drink (except water), and refrain from alcohol for 12 hours 
prior to scanning. Cigarette smokers were not permitted to smoke for four hours preceding the 
scan 2.  
18F-DOPA synthesis and PET data acquisition 
A 17MeV GE PET-trace cyclotron was used for radionuclide production. The gas target was filled 
with 18O2 and bombarded at 40 mA for 30 min followed by a passivation bombardment of 0.1% F2 
in argon at 20 mA for 20 min. This produced 18F-F by the 18O (p,n) 18F reaction. An electrophilic 
fluorination procedure was then used to synthesize 6-18F fluoro-L-DOPA. In brief, [18F]F2 was 
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bubbled through a solution of 6-trimethylstannyl-L-DOPA (60 mg) stirring in Deutero-chloroform (5 
ml) over 20 mins at 5 1C. 6 M HCl (2 ml) was added and the chloroform evaporated at 70 1C. The 
resulting aqueous mixture was heated at reflux for 10 mins before allowing to cool. The cooled 
crude mixture was purified by semi-prep high-pressure liquid chromatography polymer X column 
eluting with ammonium acetate buffer. The peak corresponding to 18F-L-DOPA eluted at 15 mins 
was stabilized with 1 mg ascorbic acid and sodium phosphate dibasic. For quality assurance 
purposes, a sample was taken from each synthesis and analyzed by reverse phase high-pressure 
liquid chromatography to confirm identity and purity. To proceed with the injection, a 
radiochemical purity of 95.0% or higher was required.  
PET data analysis 
Correction for head movement during scan was performed by denoising the non-attenuation-
corrected dynamic images using a level 2, order 64 Battle-Lemarie wavelet filter.  Frames were 
realigned to a single reference frame, acquired 20 mins post-injection, employing a mutual 
information algorithm 3,4. The transformation parameters were then applied to the corresponding 
attenuated-corrected dynamic images, creating a movement-corrected dynamic image, which was 
used in the analysis. Realigned frames were then summated to create an individual motion-
corrected reference map for the brain tissue segmentation.  SPM85  was used to normalize a tracer-
specific (18F-DOPA) template 6,7 together with the a striatal probabilistic brain atlas defined by 
Martinez et al 8 both in the same space to each individual PET summation image. The brain atlas 
was used to identify the whole striatum, functional striatal subdivisions and the cerebellar region 
used as reference for tissue quantification 8. The striatal influx constant (Kicer, written as Ki in some 
previous publications 7) was calculated compared with uptake in the reference region using the 
Patlak-Gjedde graphical approach adapted for a reference tissue input function 6. A previous 
test/re-test study has shown this approach has good reliability 6. Further details of the image 
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analysis approach are given in Bloomfield et al2.  
Though the reference region approach is robust to global differences in radiotracer delivery to the 
brain9, we examined the reference region (cerebellum) to see whether there was any change in 
standardized uptake value (SUV) in the cerebellum at 95 minutes.  
Striatal volume measures were derived from the atlas based segmentation as the number of voxels 
in the striatal region times the volume of a single PET image voxel (voxel volume = 2.05mm x 
2.05mm x 2mm = 8.41mm3). This analysis was undertaken to investigate the possible presence of 
partial volume differences between groups.  
 
PET parametric mapping 
We implemented a previously established method10 in which Kicer parametric images of the brain 
were constructed from motion-corrected images using a wavelet-based approach11. The parametric 
image for each participant was then normalized into Montreal Neurological Institute standard 
space (matrix dimension: 91x109x91; voxel size: 2mm isotropic) using the participant’s PET 
summation image and the 18F-DOPA template. Statistical parametric mapping was conducted using 
SPM8 using a striatal mask10 to compare striatal dopamine synthesis capacity between responders 
and non-responders using an independent t-test. Results are presented corrected for multiple 
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Amisulpride, N=5  
Aripiprazole, N=2 
Olanzapine, N=1  
Quetiapine, N=2 
Risperidone, N=1  
Lurasidone, N=1 




Amisulpride, N=1  
Aripiprazole, N=1  
Olanzapine, N=4 
Quetiapine, N=1  
Quetiapine and Sertraline, N=1 
 
Amisulpride and Quetiapine 
N=1 
Risperidone and Aripiprazole, 
N=1 
Risperidone and Mirtazapine, 
N=1  
Paliperidone N=1 
Aripiprazole depot N=1 
 
 




Chlorpromazine equivalent  
(dose years) prior to scan         
(Median, IQR)   
0 (0.1) 0 (0.3) p=0.46 
Chlorpromazine equivalents 
(dose years) between scan and 
follow-up clinical assessment 
 
0.38 (0.29)  0.53 (0.35) p=0.26 
Supplementary Table 2 Psychotropic medication 
At six-month follow-up, all PANSS response criteria responders met criteria for remission, ands 1 of 
the 13 PANSS criteria non-responders fulfilled criteria for remission.  
All CGI-I responders met remission criteria, whilst all CGI-I non-responders continued to meet the 
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Supplementary Table 3 
























n 26  1 3 6 2 9 5 





















reduction   
 26 3 8 2 7 6   
 
  




Supplementary Table 4 Dopamine synthesis capacity in striatal sub-regions 
 
Striatal region Mean (sd) 
Kicer Responder 
(n=13) 
Mean (sd) Kicer 
Non-responder  
(n=13) 




(sig at p=0.01) 
13.38 x 10-3  
(0.74 x 10-3) 
12.27 x 10-3  
(0.92 x 10-3) 
12.26 x 10-3  




(0.78 x 10-3) 
12.12 x 10 -3  
(0.93x10-3) 
12.17 x 10-3  
(1.14 x 10-3) 
Limbic Striatum 12.98 x 10-3 
(0.76 x 10-3) 
12.35 x 10-3             
(0.87 x 10-3) 
12.14 x 10-3 (                        
(1.25 x 10-3) 
Sensorimotor 
Striatum 
13.41 x 10-3 
(0.92x 10-3) 
12.6 x 10-3                                 
(1.1 x 10-3) 
12.53 x 10-3                          
(1.44 x 10-3   
 
SUV analysis 
We conducted an ANCOVA, with SUV in the reference region as a covariate, to see if tracer uptake 
in the cerebellum may account for our results, using the reference region (cerebellum) approach. 
This did not change the results, F (2,56)=5.74, p=0.01. 
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